VYNE THERAPEUTICS INC VYNE 深 滬
等待開盤 08-01 09:30:00 美东时间
0.3656
-0.032
-8.16%
華盛通- 最 高0.4099
- 今 開0.40
- 成交量 644.55万股
- 最 低 0.3403
- 昨 收 0.3981
- 總市值 609.27万
- 52周最高 4.30
- 市盈率 靜 --
- 換手率 38.68%
- 52周最低 0.3403
- 委 比 30.82%
- 總股本 1666.49万
- 歷史最高 2869.92
- 量 比 0.80
- 振 幅 17.48%
- 歷史最低 0.3403
- 每 手 1
- 風險率 0.55%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多HC Wainwright & Co. Downgrades VYNE Therapeutics to Neutral
HC Wainwright & Co. analyst Joseph Pantginis downgrades VYNE Therapeutics (NASDAQ:VYNE) from Buy to Neutral.
07-30 23:20
VYNE Therapeutics Announces Phase 2b Trial With Repibresib Gel In Nonsegmental Vitiligo Did Not Meet Primary Endpoint Or Key Secondary Endpoint of F-VASI50 And F-VASI75
Trial Did Not Meet Primary Endpoint or Key Secondary Endpoint of F-VASI50 and F-VASI75Nominally Statistically Significant Effects Observed in Key Secondary and Exploratory Endpoints of Change from Baseline in F-VASI and
07-30 20:08
VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202
VYNE Therapeutics provided an update on its VYN202 program following a clinical hold by the FDA in April. The FDA lifted the hold for female patients on 0.25 mg and 0.5 mg doses in the Phase 1b psoriasis trial, while the 1 mg dose was excluded due to safety concerns. Preliminary data showed improvement in psoriasis symptoms and cytokine levels for VYN202-treated subjects. The company will not enroll new patients in the psoriasis trial and will fo...
07-02 11:45
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Plus Therapeutics (NASDAQ:PSTV) stock increased by 66.2% to $0.31 duri...
06-26 01:06
VYNE Therapeutics Q1 EPS $(0.20) Beats $(0.29) Estimate, Sales $202.00K Beat $50.00K Estimate
VYNE Therapeutics (NASDAQ:VYNE) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.29) by 31.03 percent. This is a 33.33 percent decrease over losses of $(0.15) per share from
05-08 20:06
Why Paymentus Holdings Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket
Shares of Paymentus Holdings, Inc. (NYSE:PAY) rose sharply in today's pre-marke...
03-11 18:55
VYNE Therapeutics Reports Progress in Clinical Trials
Vyne Therapeutics Inc ( ($VYNE) ) has released its Q4 earnings. Here is a break...
03-08 11:57
VYNE Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
Analysts' ratings for VYNE Therapeutics (NASDAQ:VYNE) over the last quarter var...
03-07 03:02
美股大行评级 | Maxim Group：维持Adeia"买入"评级，目标价从15美元升至17美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1099616672362106881.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Maxim Group：维持Chemomab Therapeutics(CMMB)"买入"评级，目标价从4美元升至7美元</p> <p>• B. Riley证券：维持全球星(GSAT)"买入"评级，目标价从4美元调整至60
02-21 13:48
VYNE Therapeutics: Strategic Pipeline Advancements and Promising Clinical Outlook
VYNE Therapeutics (VYNE – Research Report), the Healthcare sector company, was ...
01-14 19:26
